Maraviroc (MVC), a small‐molecule CCR5 antagonist that prevents the entry of HIV into host cells, has also been used experimentally and clinically to inhibit TAMs recruitment and M2 polarization to improve cancer progression.93, 94, 95, 96, 97. This evidence concerns the gene CCR5 and cancer.